Description

Epirubicin Amaxa (epirubicin) solution for injections 2 mg/ml. 5 ml. vial №1

Ingredients

Epirubicin Amaxa contains epirubicin as the active ingredient. Each milliliter of the solution for injection contains 2 mg of epirubicin hydrochloride.

Dosage

The dosage of Epirubicin Amaxa should be determined by a healthcare professional based on the patient’s condition, weight, and other factors. It is usually administered intravenously.

Indications

Epirubicin Amaxa is indicated for the treatment of various types of cancer, including breast cancer, stomach cancer, lung cancer, and ovarian cancer.

Contraindications

Epirubicin Amaxa is contraindicated in patients with a history of severe allergic reactions to epirubicin or any of the ingredients in the formulation.

Directions

Epirubicin Amaxa should be administered under the supervision of a healthcare provider experienced in the use of chemotherapy agents. The injection site should be carefully monitored for any signs of extravasation.

Scientific Evidence

Epirubicin, the active ingredient in Epirubicin Amaxa, is a semi-synthetic anthracycline derivative with potent antineoplastic properties. Studies have shown that epirubicin inhibits DNA and RNA synthesis in cancer cells, leading to cell death. Clinical trials have demonstrated the efficacy of epirubicin in the treatment of various cancers, both as a single agent and in combination with other chemotherapy drugs.

Additional Information

It is important to monitor cardiac function during treatment with epirubicin, as it can cause cardiotoxicity. Patients receiving Epirubicin Amaxa should undergo regular cardiac assessments to detect any signs of cardiac damage early. Additionally, precautions should be taken to avoid exposure of healthcare providers to the drug, as it is cytotoxic.

Epirubicin Amaxa is a vital chemotherapy agent used in the treatment of a wide range of cancers. Its mechanism of action involves intercalation into DNA strands, leading to the inhibition of nucleic acid synthesis and ultimately cell death. The drug has shown efficacy in both early and advanced stages of cancer, making it a valuable component of many treatment regimens.

Clinical trials have highlighted the effectiveness of Epirubicin Amaxa in improving survival rates and reducing tumor size in various cancer types. Research has also focused on optimizing dosing schedules and exploring combination therapies to enhance the drug’s anticancer effects. The continuous evaluation of epirubicin in clinical settings underscores its importance in modern oncology.